VYCOR MEDICAL, INC.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $418.3K | $458.5K | $416.9K | $513.8K | $496.4K | $436.4K | $455.2K | $390.9K |
| Cost of Revenue | $73.8K | $83.4K | $81.5K | $61.9K | $81.1K | $77.8K | $57.8K | $36.8K |
| Gross Profit | $344.4K | $375.2K | $335.4K | $451.9K | $415.3K | $358.5K | $397.4K | $354.1K |
| Gross Margin | 82.4% | 81.8% | 80.4% | 88.0% | 83.7% | 82.2% | 87.3% | 90.6% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | $4.2K | $5.8K | — | $6.4K |
| SG&A Expense | $322.7K | $315.4K | $357.0K | $405.0K | $345.0K | $350.7K | $356.5K | $367.9K |
| Operating Income | $6.9K | $45.8K | $-36.5K | $32.1K | $51.1K | $-12.8K | $19.3K | $-35.1K |
| Operating Margin | 1.6% | 10.0% | -8.8% | 6.2% | 10.3% | -2.9% | 4.2% | -9.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-19.1K | $20.1K | $-62.4K | $5.0K | $25.7K | $-38.5K | $-6.7K | $-59.8K |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-22.3K | $20.1K | $-62.7K | $4.9K | $23.9K | $-38.6K | $-6.7K | $-59.8K |
| Net Margin | -5.3% | 4.4% | -15.0% | 1.0% | 4.8% | -8.8% | -1.5% | -15.3% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.01 | $-0.01 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.01 | $-0.01 |
| Shares Outstanding (Basic) | 33.4M | 33.4M | 33.4M | 33.4M | 33.4M | 33.4M | 32.9M | 32.9M |
| Shares Outstanding (Diluted) | 33.4M | 33.4M | 33.4M | 33.4M | 38.7M | 33.4M | 32.9M | 32.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |